Epilepsy and epileptic syndrome

Research output: Chapter in Book/Report/Conference proceedingChapter

15 Citations (Scopus)

Abstract

Epilepsy is one of the most common neurological disorders. In most patients with epilepsy, seizures respond to available medications. However, a significant number of patients, especially in the setting of medically-intractable epilepsies, may experience different degrees of memory or cognitive impairment, behavioral abnormalities or psychiatric symptoms, which may limit their daily functioning. As a result, in many patients, epilepsy may resemble a neurodegenerative disease. Epileptic seizures and their potential impact on brain development, the progressive nature of epileptogenesis that may functionally alter brain regions involved in cognitive processing, neurodegenerative processes that relate to the underlying etiology, comorbid conditions or epigenetic factors, such as stress, medications, social factors, may all contribute to the progressive nature of epilepsy. Clinical and experimental studies have addressed the pathogenetic mechanisms underlying epileptogenesis and neurodegeneration. We will primarily focus on the findings derived from studies on one of the most common causes of focal onset epilepsy, the temporal lobe epilepsy, which indicate that both processes are progressive and utilize common or interacting pathways. In this chapter we will discuss some of these studies, the potential candidate targets for neuroprotective therapies as well as the attempts to identify early biomarkers of progression and epileptogenesis, so as to implement therapies with early-onset disease-modifying effects.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages99-113
Number of pages15
Volume724
DOIs
StatePublished - 2012

Publication series

NameAdvances in Experimental Medicine and Biology
Volume724
ISSN (Print)00652598

Fingerprint

Epilepsy
Brain
Neurodegenerative diseases
Biomarkers
Data storage equipment
Processing
Partial Epilepsy
Temporal Lobe Epilepsy
Nervous System Diseases
Epigenomics
Neurodegenerative Diseases
Psychiatry
Seizures
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ono, T., & Galanopoulou, A. S. (2012). Epilepsy and epileptic syndrome. In Advances in Experimental Medicine and Biology (Vol. 724, pp. 99-113). (Advances in Experimental Medicine and Biology; Vol. 724). https://doi.org/10.1007/978-1-4614-0653-2_8

Epilepsy and epileptic syndrome. / Ono, Tomonori; Galanopoulou, Aristea S.

Advances in Experimental Medicine and Biology. Vol. 724 2012. p. 99-113 (Advances in Experimental Medicine and Biology; Vol. 724).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ono, T & Galanopoulou, AS 2012, Epilepsy and epileptic syndrome. in Advances in Experimental Medicine and Biology. vol. 724, Advances in Experimental Medicine and Biology, vol. 724, pp. 99-113. https://doi.org/10.1007/978-1-4614-0653-2_8
Ono T, Galanopoulou AS. Epilepsy and epileptic syndrome. In Advances in Experimental Medicine and Biology. Vol. 724. 2012. p. 99-113. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-0653-2_8
Ono, Tomonori ; Galanopoulou, Aristea S. / Epilepsy and epileptic syndrome. Advances in Experimental Medicine and Biology. Vol. 724 2012. pp. 99-113 (Advances in Experimental Medicine and Biology).
@inbook{81d4eae016914dbdbab86c323886b440,
title = "Epilepsy and epileptic syndrome",
abstract = "Epilepsy is one of the most common neurological disorders. In most patients with epilepsy, seizures respond to available medications. However, a significant number of patients, especially in the setting of medically-intractable epilepsies, may experience different degrees of memory or cognitive impairment, behavioral abnormalities or psychiatric symptoms, which may limit their daily functioning. As a result, in many patients, epilepsy may resemble a neurodegenerative disease. Epileptic seizures and their potential impact on brain development, the progressive nature of epileptogenesis that may functionally alter brain regions involved in cognitive processing, neurodegenerative processes that relate to the underlying etiology, comorbid conditions or epigenetic factors, such as stress, medications, social factors, may all contribute to the progressive nature of epilepsy. Clinical and experimental studies have addressed the pathogenetic mechanisms underlying epileptogenesis and neurodegeneration. We will primarily focus on the findings derived from studies on one of the most common causes of focal onset epilepsy, the temporal lobe epilepsy, which indicate that both processes are progressive and utilize common or interacting pathways. In this chapter we will discuss some of these studies, the potential candidate targets for neuroprotective therapies as well as the attempts to identify early biomarkers of progression and epileptogenesis, so as to implement therapies with early-onset disease-modifying effects.",
author = "Tomonori Ono and Galanopoulou, {Aristea S.}",
year = "2012",
doi = "10.1007/978-1-4614-0653-2_8",
language = "English (US)",
isbn = "9781461406525",
volume = "724",
series = "Advances in Experimental Medicine and Biology",
pages = "99--113",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Epilepsy and epileptic syndrome

AU - Ono, Tomonori

AU - Galanopoulou, Aristea S.

PY - 2012

Y1 - 2012

N2 - Epilepsy is one of the most common neurological disorders. In most patients with epilepsy, seizures respond to available medications. However, a significant number of patients, especially in the setting of medically-intractable epilepsies, may experience different degrees of memory or cognitive impairment, behavioral abnormalities or psychiatric symptoms, which may limit their daily functioning. As a result, in many patients, epilepsy may resemble a neurodegenerative disease. Epileptic seizures and their potential impact on brain development, the progressive nature of epileptogenesis that may functionally alter brain regions involved in cognitive processing, neurodegenerative processes that relate to the underlying etiology, comorbid conditions or epigenetic factors, such as stress, medications, social factors, may all contribute to the progressive nature of epilepsy. Clinical and experimental studies have addressed the pathogenetic mechanisms underlying epileptogenesis and neurodegeneration. We will primarily focus on the findings derived from studies on one of the most common causes of focal onset epilepsy, the temporal lobe epilepsy, which indicate that both processes are progressive and utilize common or interacting pathways. In this chapter we will discuss some of these studies, the potential candidate targets for neuroprotective therapies as well as the attempts to identify early biomarkers of progression and epileptogenesis, so as to implement therapies with early-onset disease-modifying effects.

AB - Epilepsy is one of the most common neurological disorders. In most patients with epilepsy, seizures respond to available medications. However, a significant number of patients, especially in the setting of medically-intractable epilepsies, may experience different degrees of memory or cognitive impairment, behavioral abnormalities or psychiatric symptoms, which may limit their daily functioning. As a result, in many patients, epilepsy may resemble a neurodegenerative disease. Epileptic seizures and their potential impact on brain development, the progressive nature of epileptogenesis that may functionally alter brain regions involved in cognitive processing, neurodegenerative processes that relate to the underlying etiology, comorbid conditions or epigenetic factors, such as stress, medications, social factors, may all contribute to the progressive nature of epilepsy. Clinical and experimental studies have addressed the pathogenetic mechanisms underlying epileptogenesis and neurodegeneration. We will primarily focus on the findings derived from studies on one of the most common causes of focal onset epilepsy, the temporal lobe epilepsy, which indicate that both processes are progressive and utilize common or interacting pathways. In this chapter we will discuss some of these studies, the potential candidate targets for neuroprotective therapies as well as the attempts to identify early biomarkers of progression and epileptogenesis, so as to implement therapies with early-onset disease-modifying effects.

UR - http://www.scopus.com/inward/record.url?scp=84859487568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859487568&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-0653-2_8

DO - 10.1007/978-1-4614-0653-2_8

M3 - Chapter

C2 - 22411237

AN - SCOPUS:84859487568

SN - 9781461406525

VL - 724

T3 - Advances in Experimental Medicine and Biology

SP - 99

EP - 113

BT - Advances in Experimental Medicine and Biology

ER -